Friday, 16 October 2026European Markets

VISTIN PHARMA Stock Went Up By Over 12% At Session Start On Friday

Loading stream...

(VIANEWS) - Shares of VISTIN PHARMA (Oslo Børs All-share Index_GI: VISTN.OL) jumped by a staggering 12.91% to kr18.80 at 10:41 EST on Friday, following the last session's upward trend. Oslo Børs All-share Index_GI is sliding 0.78% to kr1,405.92, after five consecutive sessions in a row of losses. This seems, as yet, a somewhat down trend trading session today.

About VISTIN PHARMA

Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin hydrochloride APIs and direct compressive granulates for the pharmaceutical industry. The company was incorporated in 2015 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr0.96.

PE Ratio

VISTIN PHARMA has a trailing twelve months price to earnings ratio of 19.58. Meaning, the purchaser of the share is investing kr19.58 for every norwegian krone of annual earnings.

Volume

Today's last reported volume for VISTIN PHARMA is 58691 which is 298.95% above its average volume of 14711.

Volatility

VISTIN PHARMA's last week, last month's, and last quarter's current intraday variation average was a negative 0.61%, a negative 0.13%, and a positive 2.18%.

VISTIN PHARMA's highest amplitude of average volatility was 2.76% (last week), 1.15% (last month), and 2.18% (last quarter).

More news about VISTIN PHARMA (VISTN.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com